{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:12:23Z","timestamp":1788873143407,"version":"build-2803163510"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports on the epidemiology, diagnosis, pathological features, surgical management, and use of systemic therapies for cutaneous apocrine carcinoma. Diagnosing cutaneous apocrine carcinoma requires presenting with distinctive pathological features and excluding metastatic adenocarcinomas, particularly breast cancer. Clinical findings are essential to exclude metastatic adenocarcinomas, and immunohistochemistry can be used as an adjunctive tool to rule out other diseases. Wide local excision is the standard treatment for resectable cutaneous apocrine carcinomas. Prophylactic lymphadenectomy should be considered as a treatment option given the high incidence of lymph node metastasis. Generally, cutaneous apocrine carcinomas are resistant to chemotherapy and radiation therapy; however, adjuvant radiotherapy is recommended for high-risk patients. Radiation or systemic therapy is administered to patients with distant metastases or recurrence. The systemic therapeutic options include cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immune checkpoint inhibitors. Given the lack of data on clinical prognosis and standardized treatments, further studies are needed to improve our understanding of cutaneous apocrine carcinomas.<\/jats:p>","DOI":"10.1093\/jjco\/hyae103","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T01:15:04Z","timestamp":1722388504000},"page":"1135-1140","source":"Crossref","is-referenced-by-count":11,"title":["A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7301-1810","authenticated-orcid":false,"given":"Seiji","family":"Tsuruta","sequence":"first","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo,","place":["Japan"]},{"name":"Department of Dermatology , Faculty of Medicine, , Saga,","place":["Japan"]},{"name":"Saga University , Faculty of Medicine, , Saga,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-7100","authenticated-orcid":false,"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-8182","authenticated-orcid":false,"given":"Eiji","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2024110408211862800_ref1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jso.22023","article-title":"Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, optimal therapy for a rare neoplasm","volume":"105","author":"Hollowell","year":"2012","journal-title":"J Surg Oncol"},{"key":"2024110408211862800_ref2","first-page":"159","volume-title":"WHO Classification of Skin Tumours","author":"Elder","year":"2018","edition":"4th"},{"key":"2024110408211862800_ref3","first-page":"591","article-title":"Tumors of sweat glands","volume":"19","author":"Gates","year":"1943","journal-title":"Am J Pathol"},{"key":"2024110408211862800_ref4","first-page":"123","article-title":"Pathology of sweat gland carcinoma","volume":"3","author":"Berg","year":"1968","journal-title":"Pathol Annu"},{"key":"2024110408211862800_ref5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jaad.2022.04.052","article-title":"Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: a population-based study","volume":"88","author":"Gibbs","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024110408211862800_ref6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0190-9622(00)90136-1","article-title":"Tumors arising in nevus sebaceus: a study of 596 cases","volume":"42","author":"Cribier","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"2024110408211862800_ref7","first-page":"291","article-title":"Primary cutaneous apocrine carcinoma arising within a nevus sebaceus","volume":"102","author":"Edgar","year":"2018","journal-title":"Cutis"},{"key":"2024110408211862800_ref8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1524-4725.1990.tb00066.x","article-title":"Apocrine adenocarcinoma: case report and review of the literature","volume":"16","author":"Dhawan","year":"1990","journal-title":"J Dermatol Surg Oncol"},{"key":"2024110408211862800_ref9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/00000478-199408000-00010","article-title":"A case of apocrine adenocarcinoma associated with hamartomatous apocrine gland hyperplasia of both axillae","volume":"18","author":"Nishikawa","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"2024110408211862800_ref10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jcp.2004.021394","article-title":"Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature","volume":"58","author":"MacNeill","year":"2005","journal-title":"J Clin Pathol"},{"key":"2024110408211862800_ref11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00000421-199904000-00005","article-title":"Apocrine carcinoma of the axilla: review of the literature and recommendations for treatment","volume":"22","author":"Chamberlain","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"2024110408211862800_ref12","doi-asserted-by":"crossref","first-page":"28808","DOI":"10.1097\/MD.0000000000028808","article-title":"Primary cutaneous apocrine carcinoma of the scalp: two case reports and literature review","volume":"101","author":"Choi","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2024110408211862800_ref13","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jdcr.2020.09.002","article-title":"A slowly growing blue nodule on the scalp","volume":"6","author":"Lee","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2024110408211862800_ref14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-022-02323-5","article-title":"Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma","volume":"315","author":"Davis","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2024110408211862800_ref15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s10147-013-0594-x","article-title":"Treatment strategy for cutaneous apocrine carcinoma","volume":"19","author":"Ogata","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"2024110408211862800_ref16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s10147-023-02420-z","article-title":"Prognostic factors in cutaneous apocrine carcinoma: a single-institution retrospective study of 32 patients","volume":"28","author":"Tsuruta","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"2024110408211862800_ref17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/1346-8138.16055","article-title":"Case report of meningeal carcinomatosis in advanced cutaneous apocrine carcinoma","volume":"48","author":"Watanabe","year":"2021","journal-title":"J Dermatol"},{"key":"2024110408211862800_ref18","volume-title":"Cutaneous adnexal tumors","author":"Kazakov","year":"2012"},{"key":"2024110408211862800_ref19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181590ba4","article-title":"Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases","volume":"32","author":"Robson","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"2024110408211862800_ref20","first-page":"879","article-title":"Immunohistochemical and morphologic evaluation of primary cutaneous apocrine carcinomas and cutaneous metastases from ductal breast carcinoma","volume":"53","author":"Fernandez-Flores","year":"2012","journal-title":"Rom J Morphol Embryol"},{"key":"2024110408211862800_ref21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.5858\/2009-0445-OAR2","article-title":"An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature","volume":"135","author":"Rollins-Raval","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"2024110408211862800_ref22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.humpath.2013.09.007","article-title":"Cutaneous and mammary apocrine carcinomas have different immunoprofiles","volume":"45","author":"Piris","year":"2014","journal-title":"Hum Pathol"},{"key":"2024110408211862800_ref23","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024110408211862800_ref24","first-page":"879","volume-title":"Neoplasms with Apocrine Differentiation","author":"Requena","year":"1998"},{"key":"2024110408211862800_ref25","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927744","article-title":"Primary cutaneous cribriform apocrine carcinoma","volume":"22","author":"Boettler","year":"2021","journal-title":"Am J Case Rep"},{"key":"2024110408211862800_ref26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2009.03.032","article-title":"Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm","volume":"61","author":"R\u00fctten","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2024110408211862800_ref27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0303-6987.2005.00375.x","article-title":"Primary cutaneous cribriform carcinoma: a rare apocrine tumour","volume":"32","author":"Adamski","year":"2005","journal-title":"J Cutan Pathol"},{"key":"2024110408211862800_ref28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1684\/ejd.2017.3034","article-title":"A solid variant of primary cutaneous cribriform carcinoma: a small, stable, long-term lesion","volume":"27","author":"Yokota","year":"2017","journal-title":"Eur J Dermatol"},{"key":"2024110408211862800_ref29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jdcr.2020.01.021","article-title":"A tender pigmented papule in an African-American woman","volume":"6","author":"Williams","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2024110408211862800_ref30","first-page":"832","article-title":"Primary cutaneous cribriform apocrine carcinoma on a typical location","volume":"20","author":"Ruiz-Villaverde","year":"2010","journal-title":"Eur J Dermatol"},{"key":"2024110408211862800_ref31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cup.13124","article-title":"GATA3 staining in primary cutaneous apocrine cribriform carcinoma: usefulness to differentiate it from breast cancer metastasis","volume":"45","author":"Llamas-Velasco","year":"2018","journal-title":"J Cutan Pathol"},{"key":"2024110408211862800_ref32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00795-007-0377-4","article-title":"Immunohistochemical phenotype of cutaneous cribriform carcinoma with a panel of 15 antibodies","volume":"40","author":"Fernandez-Flores","year":"2007","journal-title":"Med Mol Morphol"},{"key":"2024110408211862800_ref33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/cup.12469","article-title":"Primary cutaneous cribriform carcinoma: report of six cases with clinicopathologic data and immunohistochemical profile","volume":"42","author":"Arps","year":"2015","journal-title":"J Cutan Pathol"},{"key":"2024110408211862800_ref34","first-page":"83","article-title":"Carcinomas of sweat glands","volume":"22","author":"Cooper","year":"1987","journal-title":"Pathol Annu"},{"key":"2024110408211862800_ref35","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/267474","article-title":"Sentinel lymph node biopsy in nonmelanoma skin cancer patients","volume":"2013","author":"Matthey-Gi\u00e8","year":"2013","journal-title":"J Skin Cancer"},{"key":"2024110408211862800_ref36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijscr.2020.10.067","article-title":"Sentinel lymph node biopsy of primary apocrine sweat gland carcinoma of the axilla: a case report and review of the literature","volume":"77","author":"Sekine","year":"2020","journal-title":"Int J Surg Case Rep"},{"key":"2024110408211862800_ref37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.canrad.2022.12.003","article-title":"Radiotherapy of skin adnexal carcinoma","volume":"27","author":"Larnaudie","year":"2023","journal-title":"Cancer Radiother"},{"key":"2024110408211862800_ref38","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1200\/JCO.2007.13.9923","article-title":"Axillary apocrine carcinoma with brain metastases","volume":"25","author":"Gallerani","year":"2007","journal-title":"J Clin Oncol"},{"key":"2024110408211862800_ref39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1022896515287","article-title":"The mammary gland and its origin during synapsid evolution","volume":"7","author":"Oftedal","year":"2002","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"2024110408211862800_ref40","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/bjd.12788","article-title":"Combination chemotherapy for metastatic extramammary Paget disease","volume":"170","author":"Oashi","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024110408211862800_ref41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1346-8138.2005.tb00812.x","article-title":"Extramammary Paget's disease\/carcinoma successfully treated with a combination chemotherapy: report of two cases","volume":"32","author":"Mochitomi","year":"2005","journal-title":"J Dermatol"},{"key":"2024110408211862800_ref42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjd.17922","article-title":"Single-agent taxane is useful in palliative chemotherapy for extramammary Paget disease: a case series","volume":"181","author":"Kato","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024110408211862800_ref43","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease","volume":"42","author":"Yoshino","year":"2016","journal-title":"J Dermatol"},{"key":"2024110408211862800_ref44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2133.2005.07046.x","article-title":"Metastatic extramammary Paget's disease successfully controlled with tumour dormancy therapy using docetaxel","volume":"154","author":"Fujisawa","year":"2006","journal-title":"Br J Dermatol"},{"key":"2024110408211862800_ref45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1346-8138.12414","article-title":"Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine","volume":"41","author":"Fujisawa","year":"2014","journal-title":"J Dermatol"},{"key":"2024110408211862800_ref46","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1200\/JCO.2009.26.1891","article-title":"Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy","volume":"28","author":"Tlemcani","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024110408211862800_ref47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-019-02334-8","article-title":"Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas","volume":"68","author":"Duverger","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2024110408211862800_ref48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2024110408211862800_ref49","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2024110408211862800_ref50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2024110408211862800_ref51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamadermatol.2016.5062","article-title":"Association between programmed death ligand 1 expression in patients with basal cell carcinomas and the number of treatment modalities","volume":"153","author":"Chang","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024110408211862800_ref52","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/bjd.14955","article-title":"The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma","volume":"176","author":"Schaper","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024110408211862800_ref53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024110408211862800_ref54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2017.11.008","article-title":"Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab","volume":"90","author":"Rogatsch","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024110408211862800_ref55","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/ccr3.3434","article-title":"Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-a case report","volume":"8","author":"Collette","year":"2020","journal-title":"Clin Case Rep"},{"key":"2024110408211862800_ref56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/modpathol.3800007","article-title":"Her-2 expression in cutaneous eccrine and apocrine neoplasms","volume":"17","author":"Hiatt","year":"2004","journal-title":"Mod Pathol"},{"key":"2024110408211862800_ref57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00019606-200109000-00001","article-title":"Her-2\/neu and breast cancer","volume":"10","author":"Kaptain","year":"2001","journal-title":"Diagn Mol Pathol"},{"key":"2024110408211862800_ref58","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot","year":"2019","journal-title":"Ann Oncol"},{"key":"2024110408211862800_ref59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"2024110408211862800_ref60","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"key":"2024110408211862800_ref61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamadermatol.2015.2507","article-title":"Metastatic cutaneous apocrine adenocarcinoma treated with a combination of pertuzumab-based targeted therapy and taxane chemotherapy: a case report","volume":"152","author":"Otsuka","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024110408211862800_ref62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2340\/00015555-1354","article-title":"Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine","volume":"92","author":"Hidaka","year":"2012","journal-title":"Acta Derm Venereol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1135\/60343168\/hyae103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/11\/1135\/60343168\/hyae103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:23:43Z","timestamp":1730708623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/11\/1135\/7724224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae103","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,7,31]]}}}